Actively Recruiting
Study of How Antimicrobial Treatments Affect the Skin Microbiome in People With Atopic Dermatitis and Healthy Volunteers
Led by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Updated on 2026-10-29
130
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how treatments for atopic dermatitis, a chronic skin condition sometimes complicated by Staphylococcus aureus infections, affect the types and quantities of bacteria on the skin. This phase 2 trial focuses on both patients with moderate to severe eczema and healthy volunteers, aiming to understand how antimicrobial treatments change the skin microbiome over time. Participants are assigned to different groups receiving various treatments, including antibiotics such as cephalexin, trimethoprimsulfamethoxazole, doxycycline, or placebo capsules. Some groups also use a dilute bleach bath or a placebo bath liquid. The treatments vary in dosage and duration, with some lasting 14 days and others up to 56 days. The study includes a randomized, placebo-controlled design with single masking and involves longitudinal sampling of the skin microbiome. During the one-year study, participants undergo regular visits for medical exams, sample collections, and possibly skin biopsies to monitor microbiome changes and treatment effects. Healthy volunteers may have an additional one-time follow-up visit after one year. Researchers will assess microbiome alterations primarily within two weeks and continue to evaluate changes throughout the study duration, while also monitoring participants clinical responses and safety.
CONDITIONS
Brief Title
Effects of Treatments on Atopic Dermatitis
Research Team
H
Heidi H Kong, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here